

SUPPORTING INFORMATION

Cytotoxic polyketides from the deep-sea-derived fungus *Aspergillus fischeri* FS452

Zhaoming Liu^a, Saini Li^a, Yuchan Chen^a, Mingqiong Li^a, Hongxin Liu^a
and Weimin, Zhang^a

^a *Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, State Key Laboratory of Applied Microbiology Southern China, Institute of Microbiology, Guangdong Academy of Sciences, 100 Central Xianlie Road, Yuexiu District, Guangzhou 510070, China;*

Corresponding authors, Email: wmzhang@gdim.cn; Tel: 86-020-87237597 (W. Zhang)

Cytotoxic polyketides from the deep-sea-derived fungus *Aspergillus fischeri* FS452

Six polyketides belong to spinoate family (**1–6**) including two new ones fischerins A (**1**) and B (**2**) were isolated from the deep-sea-derived fungus *Aspergillus fischeri* FS452. Their structures were elucidated by comprehensive spectroscopic analysis and the absolute configurations were determined by the e quantum chemical ECD calculations. The *in vitro* cytotoxicity assays indicated that fischerin B (**2**) exhibited potential activities against the four tested human cancer cell lines (SF-268, MCF-7, HepG-2 and A549) with the IC₅₀ values in the range of 7 ~ 10 μM.

Keywords: polyketides; deep-sea-derived fungus; quantum chemical calculations; cytotoxicity

Table of contents:

Figure S1. The COSY (red bold lines) and the key HMBC correlations (blue arrows) of **1** and **2**.

Figure S2. The experimental ECD spectrum of **1/2** and the calculated plots of (2*S*,4*R*)-**1**/(2*S*,4*S*)-**2** at b3lyp/6-311+g(d,p) level.

Figure S3. The ortep drawing of the mixture of **5** and **6**.

Figure S4. ¹H NMR spectrum of **1** in chloroform-*d*.

Figure S5. ¹³C NMR spectrum of **1** in chloroform-*d*.

Figure S6. ¹H, ¹H-COSY spectrum of **1** in chloroform-*d*.

Figure S7. HSQC spectrum of **1** in chloroform-*d*.

Figure S8. HMBC spectrum of **1** in chloroform-*d*.

Figure S9. ¹H NMR spectrum of **2** in chloroform-*d*.

Figure S10. ¹³C NMR spectrum of **2** in chloroform-*d*.

Figure S11. ¹H, ¹H-COSY spectrum of **2** in chloroform-*d*.

Figure S12. HSQC spectrum of **2** in chloroform-*d*.

Figure S13. HMBC spectrum of **2** in chloroform-*d*.

Figure S14. HRESI TOF MS spectrum of **1**.

Figure S15. HRESI TOF MS spectrum of **2**.

Figure S16. HPLC analysis of the extract of fermented liquid, mycelia and pure compound **1/2**.

Figure S17. Chiral separation of compounds **5** and **6**.

Table S1. The ¹H and ¹³C NMR Data of **1** and **2** recorded at 600 MHz (¹H) and 150 MHz (¹³C).

Table S2. Cytotoxicity assays of **1-6**.

Table S3. Energy analysis for the Conformers of (2*S*,4*R*)-**1**.

Table S4. Energy analysis for the Conformers of (2*S*,4*S*)-**2**.

Figure S1. The COSY (red bold lines) and the key HMBC correlations (blue arrows) of **1** and **2**.




Figure S2. The experimental ECD spectrum of **1/2** and the calculated plots of $(2S,4R)$ -**1**/ $(2S,4S)$ -**2** at b3lyp/6-311+g(d,p) level.




Figure S3. The ortep drawing of the mixture of **5** and **6**.




Figure S4. ^1H NMR spectrum of **1** in chloroform-*d*.




Figure S5. ^{13}C NMR spectrum of **1** in chloroform-*d*.




Figure S6. ^1H , ^1H -COSY spectrum of **1** in chloroform-*d*.




Figure S7. HSQC spectrum of **1** in chloroform-*d*.




Figure S8. HMBC spectrum of **1** in chloroform-*d*.




Figure S9. $^1\text{H-NMR}$ spectrum of **2** in chloroform-*d*.




Figure S10. ^{13}C -NMR spectrum of **2** in chloroform-*d*.




Figure S11. ^1H , ^1H -COSY spectrum of **2** in chloroform-*d*.




Figure S12. HSQC spectrum of **2** in chloroform-*d*.




Figure S13. HMBC spectrum of **2** in chloroform-*d*.





Figure S14. HRESI TOF MS spectrum of **1**.

Acquisition Parameter					
Source Type	ESI	Ion Polarity	Negative	Set Nebulizer	0.4 Bar
Focus	Active	Set Capillary	3800 V	Set Dry Heater	180 °C
Scan Begin	70 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1500 m/z	Set Charging Voltage	0 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C



SPECTRUM -


simulation :

m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
297.0979	297.0980	0.2	6.5	C14 H17 O7

Figure S15. HRESI TOF MS spectrum of **2**.

Acquisition Parameter

Source Type	ESI	Ion Polarity	Negative	Set Nebulizer	0.4 Bar
Focus	Active	Set Capillary	3800 V	Set Dry Heater	180 °C
Scan Begin	70 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1500 m/z	Set Charging Voltage	0 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C




SPECTRUM -

simulation :

m/z	Theo. Mass	Delta (ppm)	RDB equiv.	Composition
297.0978	297.0980	-0.6	6.5	C14 H17 O7

Figure S16. HPLC analysis of the extract of fermented liquid, mycelia and pure compound 1/2.



Chromatographic condition: Inertsil ODS-3 column; Methanol/H₂O, 35/75 to 100/0; 1 mL/min; 280 nm. (Red: extract of fermented liquid by EtOAc; Blue: extract of mycelia by methanol)

Figure S17. Chiral separation of compounds **5** and **6**.




Table S1. The ^1H and ^{13}C NMR Data of **1** and **2** recorded at 600 MHz (^1H) and 150 MHz (^{13}C).

position	1 ^a		2 ^a	
	δ_{C} , <i>mult.</i>	δ_{H} (<i>J</i> in Hz)	δ_{C} , <i>mult.</i>	δ_{H} (<i>J</i> in Hz)
1	175.3, C		173.9, C	
2	76.7, CH	4.11, dd (10.4, 3.1)	76.3, CH	3.95, dd (5.9, 3.8)
3	37.4, CH ₂	2.28, ddd (14.6, 10.4, 3.1) 2.09, ddd (14.6, 10.5, 3.1)	35.6, CH ₂	2.43, ddd (14.8, 9.9, 3.8) 2.28, ddd (14.8, 5.9, 4.0)
4	75.4, CH	5.14, dd (10.5, 3.1)	74.6, CH	5.14, dd (9.9, 4.0)
5	110.7, C		110.7, C	
6	163.1, C		163.3, C	
7	113.1, C		113.1, C	
8	132.0, CH	7.59, d (8.8)	132.1, CH	7.60, d (8.9)
9	108.8, C	6.41, d (8.8)	109.0, C	6.42, d (8.9)
10	162.0, C		162.0, C	
11	202.8, C		202.9, C	
12	26.1, CH ₃	2.54, s	26.1, CH ₃	2.55, s
13	58.7, CH ₃	3.51, s	58.1, CH ₃	3.55, s
14	58.1, CH ₃	3.46, s	58.0, CH ₃	3.40, s
OH		13.13, s		13.15

^aMeasured in chloroform-*d*.

Table S2. Cytotoxicity assays of **1–6**.

Compounds	SF-268	MCF-7	HepG-2	A549
1	> 100	> 100	> 100	> 100
2	7.56 ± 0.20 ^a	8.45 ± 0.27	9.03 ± 0.26	9.98 ± 0.42
3	> 100	> 100	> 100	> 100
4	> 100	> 100	> 100	> 100
5	> 100	> 100	> 100	> 100
6	> 100	> 100	> 100	> 100
<i>cis</i> -platinum	3.26 ± 0.29	3.19 ± 0.12	2.42 ± 0.14	1.56 ± 0.08

^aIC₅₀ in μM; ^bNot tested.

Table S3. Energy analysis for the conformers of (2*S*,4*R*)-1.

compounds	Conformation	G (Hartree)	G (Kcal/mol)	ΔG (Kcal/mol)	Boltzma nn Dist (%)
1	1-1	-1071.24307103	-672208.1337	0.00	53.59%
	1-2	-1071.24170473	-672207.2763	0.86	12.59%
	1-3	-1071.24130135	-672207.0232	1.11	8.21%
	1-4	-1071.24188587	-672207.39	0.74	15.26%
	1-5	-1071.24129049	-672207.0164	1.12	8.12%
	1-6	-1071.24006885	-672206.2498	1.88	2.22%













**1-1****1-2****1-3****1-4****1-5****1-6**

Table S4. Energy analysis for the Conformers of (2*S*,4*S*)-2.

compounds	Conformation	G (Hartree)	G (Kcal/mol)	ΔG (Kcal/mol)	Boltzmann Dist (%)
2	2-1	-1071.23645731	-672203.9835	1.14	4.60%
	2-2	-1071.23826016	-672205.1148	0.00	31.08%
	2-3	-1071.23826731	-672205.1193	0.00	31.32%
	2-4	-1071.23726841	-672204.4925	0.63	10.87%
	2-5	-1071.23778509	-672204.8167	0.30	18.79%
	2-6	-1071.23615786	-672203.7956	1.32	3.35%

**2-1****2-2****2-3****2-4****2-5****2-6**